Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Tocilizumab: CAR T-cell therapy in DLBCL

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR T-cell therapy for treatment of cytokine release syndrome (CRS) in refractory diffuse large B-cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).